Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 501–600 of 1,038
Current status, problems, and perspectives of non-alcoholic fatty liver disease research
Tanaka, N., Kimura, T., Fujimori, N., Nagaya, T., Komatsu, M., & Tanaka, E. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i2.163 · Cited by 138
Nagarajan, S. R., Paul-Heng, M., Krycer, J. R., Fazakerley, D. J., Sharland, A. F., & Hoy, A. J. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00365.2018 · Cited by 130
JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease
Tarantino, G. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i33.3785 · Cited by 142
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 154
“The appearance is that of micro- and macro-droplets, which, at least initially, act as a type of inert form with a protective role against the ongoing lipotoxic cell injury [17,73].”
BackgroundInfluentialOmega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
“Of the TAG in the liver, 59% was derived from NEFA mobilized from adipose tissue, 26% was derived from DNL and 15% was derived from the diet (Donnelly et al., 2005).”
BackgroundNewly diagnosed diabetes mellitus as a risk factor for serious liver disease
Porepa, L., Ray, J., Sanchez-Romeu, P., & Booth, G. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.092144 · Cited by 133
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141
“Recently, quantification of the relative contribution of various sources to hepatic triglycerides in patients with nonalcoholic fatty liver disease revealed that, even under fasting conditions, a significant proportion of liver triglycerides originated from de novo lipogenesis (11).”
BackgroundCharacteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis
Yamada, K., Mizukoshi, E., Sunagozaka, H., Arai, K., Yamashita, T., Takeshita, Y., Misu, H., Takamura, T., Kitamura, S., Zen, Y., et al. (2015) · Liver International · doi:10.1111/liv.12685 · Cited by 139
“The close involvement of insulin resistance in both pathways has been clarified (20, 21).”
BackgroundThe Influence of Dietary Fat on Liver Fat Accumulation
Green, C., & Hodson, L. (2014) · Nutrients · doi:10.3390/nu6115018 · Cited by 128
“Dietary fatty acids have been reported to contribute 2%–28% of VLDL-TG [48–51].”
BackgroundMethodInfluentialInfluence of Dietary Macronutrients on Liver Fat Accumulation and Metabolism
Parry, S. A., & Hodson, L. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2017-000524 · Cited by 132
Adipose tissue in obesity and obstructive sleep apnoea
Bonsignore, M. R., McNicholas, W. T., Montserrat, J. M., & Eckel, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00047010 · Cited by 137
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Kostapanos, M. S. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i9.470 · Cited by 138
The Role of Dietary Sugars and De novo Lipogenesis in Non-Alcoholic Fatty Liver Disease
Moore, J., Gunn, P., & Fielding, B. (2014) · Nutrients · doi:10.3390/nu6125679 · Cited by 133
“[111] were able to directly assess DNL in obese and morbidly obese individuals undergoing a scheduled liver biopsy.”
BackgroundClinical approaches to non-alcoholic fatty liver disease
Schwenger, K. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1712 · Cited by 133
Dubuquoy, C., Robichon, C., Lasnier, F., Langlois, C., Dugail, I., Foufelle, F., Girard, J. R., Burnol, A., Postic, C., & Moldes, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.024 · Cited by 148
Xia, M.-F., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 132
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease
Guerrerio, A. L., Colvin, R. M., Schwartz, A. K., Molleston, J. P., Murray, K. F., Diehl, A., Mohan, P., Schwimmer, J. B., Lavine, J. E., Torbenson, M. S., et al. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.020156 · Cited by 148
Winn, N. C., Liu, Y., Rector, R. S., Parks, E. J., Ibdah, J. A., & Kanaley, J. A. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.012 · Cited by 150
“The pathogenesis of fatty liver is multifactorial, caused by an imbalance among fatty acid influx from the diet and adipose tissue lipolysis, de novo lipogenesis, and disposal of NEFAs via beta-oxidation and/or very-low-density lipoprotein secretion [53, 54].”
Self-citationDirect and indirect control of hepatic glucose production by insulin
Lewis, G. F., Carpentier, A. C., Pereira, S., Hahn, M., & Giacca, A. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.007 · Cited by 147
Ooi, G. J., Meikle, P. J., Huynh, K., Earnest, A., Roberts, S. K., Kemp, W., Parker, B. L., Brown, W., Burton, P., & Watt, M. J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.013 · Cited by 137
Dietary Anthocyanins as Nutritional Therapy for Nonalcoholic Fatty Liver Disease
Valenti, L. V. C., Riso, P., Mazzocchi, A., Porrini, M., Fargion, S. R., & Agostoni, C. V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/145421 · Cited by 151
“Most of excess hepatic lipid content derives from increased peripheral lipolysis [36], which is caused by adipose tissue insulin resistance [37], and is a typical feature of obesity.”
BackgroundLipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 148
“During NAFLD, an imbalance between uptake and synthesis that exceeds oxidation and removal occurs; in fact, patients affected by NAFLD show an increase in both uptake and synthesis [1, 37], whereas experimental reduction of lipogenesis reverses hepatic steatosis [38, 39].”
Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids
de Castro, G. S., & Calder, P. C. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.006 · Cited by 142
“11 period after a meal with 30% of fat [71].”
BackgroundMechanisms of intrahepatic triglyceride accumulation
Ress, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i4.1664 · Cited by 132
Liang, Y., Shu, L., Zhang, Y., Deng, Y., He, Y., Chen, Y., Liu, C., Lin, C., & Yang, Q. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-017-9378-3 · Cited by 144
“found the lipid accumulation in the liver to be mostly from serum FFA in NAFLD patients [29].”
BackgroundShen, B., Feng, H., Cheng, J., Li, Z., Jin, M., Zhao, L., Wang, Q., Qin, H., & Liu, G. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15139 · Cited by 138
“PI (3,4,5) P3 stimulates AKT, which contributes to activating of mTORC1.”
BackgroundNogueira, J. P., & Cusi, K. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 110
“Impaired cellular glucose uptake response to insulin, plus an excess in fl ux of energy as FFAs from increased lipolysis of white adipose tissue, compounded by increased rates of hepatic DNL, leads to hepatic steatosis (37).”
BackgroundMusso, G., Gambino, R., De Michieli, F., Durazzo, M., Pagano, G., & Cassader, M. (2008) · Hepatology · doi:10.1002/hep.22142 · Cited by 135
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
“Kinetic studies indicate that approximately 75% of hepatic lipids (TAG/TG) in obese patients with NAFLD comes from peripheral sites (60% from nonesterified free fatty acids from lipolysis and 15% from diet), with approximately 25% arising from de novo lipogenesis [68].”
Miller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
Insulin resistance and steatosis in humans
Capeau, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74600-7 · Cited by 141
“The sources of FAs stored in the liver and secreted via lipoproteins in patients with NAFLD have been identifi ed: 60% comes from FFA; 26% from de novo lipogenesis; and 15% from diet [25].”
BackgroundZhang, X., Ji, X., Wang, Q., & Li, J. Z. (2018) · Protein & Cell · doi:10.1007/s13238-017-0436-0 · Cited by 130
“Additionally, β-oxidation of FFAs is inhibited in insulin resistance states, thus further promoting hepatic lipid accumulation (Donnelly et al., 2005, Postic and Girard, 2008, Cohen et al., 2011, Lambert et al., 2014).”
BackgroundLiver sympathetic denervation reverses obesity‐induced hepatic steatosis
Hurr, C., Simonyan, H., Morgan, D. A., Rahmouni, K., & Young, C. N. (2019) · The Journal of Physiology · doi:10.1113/jp277994 · Cited by 128
“Previous findings indicate that 60% of hepatic triglycerides are derived from plasma non-esterified FFAs (Donnelly et al. 2005), which are taken up by hepatocyte cell membrane transporters, including cluster of differentiation 36 (CD36) (Coburn et al. 2000) and fatty acid transport proteins (FATPs) (Doege et al. 2006).”
BackgroundInfluentialPhysiology and pathophysiology of liver lipid metabolism
Ponziani, F. R., Pecere, S., Gasbarrini, A., & Ojetti, V. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1056156 · Cited by 147
“As previously discussed, FAs derive from adipose tissue, de novo lipogenesis or lipolysis/autophagy [70]; patients with NAFLD have an increased availability of circulating FAs and their uptake by the liver is facilitated too [70–73].”
BackgroundMetabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“Among them, we will focus on adipokines secreted from adipose tissues that provide FA as the major source for NAFLD development [48].”
BackgroundInfluentialSato, F., Tamura, Y., Watada, H., Kumashiro, N., Igarashi, Y., Uchino, H., Maehara, T., Kyogoku, S., Sunayama, S., Sato, H., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2384 · Cited by 132
“In addition, several studies showed that dietary fat intake was closely associated with IHL (8) (10, 16).”
BackgroundFatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease
Gentile, C. L., Frye, M. A., & Pagliassotti, M. J. (2011) · BioFactors · doi:10.1002/biof.135 · Cited by 130
“, recently found that the latter source accounts for 60% of the hepatic triglyceride content in NAFLD patients [14], highlighting the importance of circulating fatty acids in the development of NAFLD.”
Therapeutic potential of green tea in nonalcoholic fatty liver disease
Masterjohn, C., & Bruno, R. S. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00440.x · Cited by 130
Bayol, S. A., Simbi, B. H., Fowkes, R. C., & Stickland, N. C. (2010) · Endocrinology · doi:10.1210/en.2009-1192 · Cited by 127
Syed‐Abdul, M. M., Parks, E. J., Gaballah, A. H., Bingham, K., Hammoud, G. M., Kemble, G., Buckley, D., McCulloch, W., & Manrique-Acevedo, C. (2020) · Hepatology · doi:10.1002/hep.31000 · Cited by 130
Self-citationA Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD
Moore, M. P., Cunningham, R. P., Dashek, R. J., Mucinski, J. M., & Rector, R. S. (2020) · Obesity · doi:10.1002/oby.22964 · Cited by 128
“Hepatic DNL is a major contributor to NAFLD development (22).”
BackgroundInfluentialInflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease
Luo, Y., & Lin, H. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.391 · Cited by 144
“In obese individuals, hepatic steatosis is intensified by the rising supply of FFA from AT to the liver.(29) Since excessive FFAs directly access the liver through portal circulation, increased concentrations of FFAs in the liver can cause synthesis of augmenting lipid, and gluconeogenesis concomitant increase in IR.”
BackgroundJNK regulation of hepatic manifestations of the metabolic syndrome
Czaja, M. J. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.08.010 · Cited by 124
Jornayvaz, F. R., Samuel, V. T., & Shulman, G. I. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104726 · Cited by 126
Kaufman, A., Abuqayyas, L., Denney, W. S., Tillman, E. J., & Rolph, T. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100057 · Cited by 131
“Geo mean fasting glucagon, ng/L (% CV) 88 (19) 93 (18) 99 (35) 85 (32) 93 (30) 89 (38) 83 (26) 93 (22) 97 (12) 93 (27)”
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 155
Turpin-Nolan, S. M., Hoy, A. J., Brown, R. D., Rudaz, C. G., Honeyman, J. E., Matzaris, M., & Watt, M. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1895-5 · Cited by 138
“Steatosis is characterised by TAG deposition and a major contributor is enhanced fatty acid availability from dysregulated adipose tissue lipolysis [ 35 ].”
BackgroundPeter, A., Cegan, A., Wagner, S., Lehmann, R., Stefan, N., Königsrainer, A., Königsrainer, I., Häring, H.-U., & Schleicher, E. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.127274 · Cited by 130
Nonalcoholic fatty liver disease as a multi-systemic disease
Fotbolcu, H., & Zorlu, E. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i16.4079 · Cited by 130
Evolving Role for Pharmacotherapy in NAFLD/NASH
Attia, S. L., Softic, S., & Mouzaki, M. (2021) · Clinical and Translational Science · doi:10.1111/cts.12839 · Cited by 129
“, conversion of carbohydrates into fatty acids by the hepatocyte).(8) Insulin resistance is an important driver of lipogenesis in the context of NAFLD.”
BackgroundLiver Fat in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Yki-Järvinen, H. (2010) · Digestive Diseases · doi:10.1159/000282087 · Cited by 126
“Studies using stable isotope tracers in humans in vivo [”
MethodGluchowski, N. L., Gabriel, K. R., Chitraju, C., Bronson, R. T., Mejhert, N., Boland, S., Wang, K., Lai, Z. W., Farese, R. V., & Walther, T. C. (2019) · Hepatology · doi:10.1002/hep.30765 · Cited by 122
“1974 much as 26% of liver TG fatty acids,(20) inhibition of DGAT2 warrants further investigation.”
BackgroundLee, C., Kim, J., & Jung, Y. (2019) · Cells · doi:10.3390/cells8101259 · Cited by 139
“Patients with NAFLD show an increased influx of FFAs into and de novo lipogenesis in the liver [47,57].”
BackgroundGarcía‐Cañaveras, J. C., Donato, M. T., Castell, J. V., & Lahoz, A. (2011) · Journal of Proteome Research · doi:10.1021/pr200629p · Cited by 141
Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation
Grattagliano, I., de Bari, O., Bernardo, T. C., Oliveira, P. J., Wang, D. Q. ‐., & Portincasa, P. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.024 · Cited by 140
Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis
Asif, S., Kim, R. Y., Fatica, T., Sim, J., Zhao, X., Oh, Y., Denoncourt, A. M., Cheung, A., Downey, M., Mulvihill, E. E., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101494 · Cited by 143
Sirtuins and nonalcoholic fatty liver disease
Nassir, F., & Ibdah, J. A. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i46.10084 · Cited by 135
Systems biology in hepatology: approaches and applications
Mardinoğlu, A., Borén, J., Smith, U., Uhlén, M., & Nielsen, J. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0007-8 · Cited by 135
The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
Li, X., Yuan, B., Lu, M. M., Wang, Y., Ding, N., Liu, C., Gao, M., Yao, Z., Zhang, S., Zhao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27539-3 · Cited by 129
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
“To balance the elevated blood glucose levels, insulin, and FFA, the liver increases the storage of fatty acids and their synthesis through de novo lipogenesis, regulated by the sterol regulatory element binding protein-1 (SREBP1c) (Donnelly et al., 2005).”
BackgroundThe Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis
Kanwar, P., & Kowdley, K. V. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.002 · Cited by 140
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
Ghetti, F. D. F., de Oliveira, D. G., de Oliveira, J. M., Ferreira, L. E. V. V. D. C., Cesar, D. E., & Moreira, A. P. B. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1524-x · Cited by 130
“On a smaller scale, the availability of fatty acids in the liver may result from the transport mediated by lipoproteins after intestinal absorption of dietary fats [21].”
BackgroundDiet, lipids, and antitumor immunity
Prendeville, H., & Lynch, L. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00781-x · Cited by 134
“NEFAs can freely diffuse into the liver, where they directly contribute to the pathogenesis of nonalcoholic fatty liver disease (NAFLD) [109].”
BackgroundRelationship between NAFLD and coronary artery disease: A Mendelian randomization study
Ren, Z., Simons, P. I. H. G., Wesselius, A., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2022) · Hepatology · doi:10.1002/hep.32534 · Cited by 140
“[4] Although these liver‐related complications contribute to increasedmortality rates, cardiovascular disease (CVD) is the leading cause of death among patients with NAFLD.”
InfluentialClinical problems caused by obesity
Kyrou, I., Randeva, H., Barber, T., Tsigos, C., Kaltsas, G. A., & Weickert, M. O. (2022) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33841351 · Cited by 127
Huh, J. Y., Reilly, S. M., Abu-Odeh, M., Murphy, A. N., Mahata, S. K., Zhang, J., Cho, Y., Seo, J. B., Hung, C., Green, C. R., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.010 · Cited by 130
Leite, N. C., Villela-Nogueira, C. A., Cardoso, C. R. L., & Salles, G. F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8377 · Cited by 142
Torre, S. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572490 · Cited by 143
“To a less extent, hepatic lipid deposits derive from dietary FAs (∼15%) and from increased synthesis of new lipids (∼25%) from ingested carbohydrates that reach to a greater extent the liver due to the insulin resistance of the muscle (43, 75, 78).”
BackgroundSubichin, M., Clanton, J., Makuszewski, M., Bohon, A., Zografakis, J. G., & Dan, A. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.06.015 · Cited by 124
“Indeed, the risk factors for NAFLD have not been significantly described, though some studies have demonstrated a close relationship between poor glycemic control and the development of NAFLD [11–13].”
BackgroundJacome-Sosa, M. M., & Parks, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000080 · Cited by 118
“After synthesis, lipogenic FA appear to move into a ‘delay’ pool that turns over slowly in the liver before contributing to a triglyceride pool destined for VLDL secretion [3].”
BackgroundSelf-citationDenzer, C., Thiere, D., Muche, R., Köenig, W., Mayer, H. G., Kratzer, W., & Wabitsch, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1125 · Cited by 138
The role of liver in metabolism: an updated review with physiological emphasis
Alamri, Z. Z. (2018) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20184211 · Cited by 152
“from 5 to 10% of the TG in the liver; while this percent is elevated to exceed 25% in NAFLD patients signifying that this process may be a main contributing factor in the occurrence of NAFLD in humans.(21,22)”
BackgroundTanaka, N., Takahashi, S., Zhang, Y., Krausz, K. W., Smith, P. B., Patterson, A. D., & Gonzalez, F. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.02.012 · Cited by 120
“Since WAT lipolysis may promote the development of hepatic steatosis and steatohepatitis [29, 40], these observations led to the hypothesis that FGF21 affects the occurrence of MCD-NASH through accelerating WAT lipolysis.”
BackgroundMechanisms and clinical implications of hepatocyte lipoapoptosis
Cazanave, S. C., & Gores, G. J. (2010) · Clinical Lipidology · doi:10.2217/clp.09.85 · Cited by 122
The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis
Moon, Y.-A. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.1.6 · Cited by 121
Taskinen, M. ‐., Söderlund, S., Bogl, L. H., Hakkarainen, A., Matikainen, N., Pietiläinen, K. H., Räsänen, S., Lundbom, N., Björnson, E., Eliasson, B., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12632 · Cited by 117
Lean non-alcoholic fatty liver disease
Wang, A. Y., Dhaliwal, J., & Mouzaki, M. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.008 · Cited by 120
The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease
Grefhorst, A., van de Peppel, I. P., Larsen, L. E., Jonker, J. W., & Holleboom, A. G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601627 · Cited by 132
“org 3 liver, it contributes up to 26% of hepatic TG concentrations in patients with NAFLD (26).”
BackgroundPharmacologic inhibition of lipogenesis for the treatment of NAFLD
Esler, W. P., & Cohen, D. E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.042 · Cited by 111
Wang, X., Hasegawa, J., Kitamura, Y., Wang, Z., Matsuda, A., Shinoda, W., Miura, N., & Kimura, K. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11097fp · Cited by 134
A Role of the Bile Salt Receptor FXR in Atherosclerosis
Hageman, J., Herrema, H., Groen, A. K., & Kuipers, F. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.197897 · Cited by 119
Dietary glycemic index and liver steatosis
Valtueña, S., Pellegrini, N., Ardigò, D., Rio, D. D., Numeroso, F., Scazzina, F., Monti, L. D., Zavaroni, I., & Brighenti, F. (2006) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.1.136 · Cited by 129
Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men
Ryu, S., Chang, Y., Kim, S. G., Cho, J., & Güallar, E. (2010) · Metabolism · doi:10.1016/j.metabol.2010.08.005 · Cited by 129
“[42] Donnelly KL, Smith CI, Schwarzenberg SJ, et al.”
BackgroundInsulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
Armandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2021) · Metabolites · doi:10.3390/metabo11030155 · Cited by 126
“In the insulin-resistant condition, the liver loses its ability to suppress HGP in response to insulin and enhances DNL through the activation of the Notch signaling pathway [48].”
BackgroundVedala, A., Wang, W., Neese, R. A., Christiansen, M. P., & Hellerstein, M. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600200-jlr200 · Cited by 117
“Isotopic studies have confirmed TG storage from NEFAs in the livers of human subjects (46, 56).”
BackgroundPathophysiological connections between gallstone disease, insulin resistance, and obesity
Cortés, V., Francisco Barrera, M., & Nervi, F. O. (2019) · Obesity Reviews · doi:10.1111/obr.12983 · Cited by 131
“SREBP1 is a transcription factor that coordinates the gene expression of multiple enzymes involved in fatty acid and triglyceride synthesis in the liver in response to insulin and its gene deletion decreases fatty liver in mice with IR.11 Thereby, BAs directly limit hepatic de novo lipogenesis by transcriptional mecha…”
BackgroundInfluentialLiu, L., Yan, H., Xia, M., Zhao, L., Lv, M., Zhao, N., Rao, S., Yao, X., Wu, W., Pan, B., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3292 · Cited by 118
“Previous studies have confirmed that liver steatosis mostly results from an increased FFA supply to the hepatocytes caused by increased lipolysis and increased intake of dietary fat.(25) It has been fully identified that exenatide can reduce body weight through delaying gastric emptying and suppressing appetite,(7,11)…”
BackgroundLiver fat and lipid oxidation in humans
Kotronen, A., Seppälä‐Lindroos, A., Vehkavaara, S., Bergholm, R., Frayn, K. N., Fielding, B. A., & Yki‐Järvinen, H. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02076.x · Cited by 115
“De novo lipogenesis also appears to be increased in NAFLD (4), but data have been sparse regarding FFA oxidation.”
BackgroundHyperpolarized [2-13C]-Fructose: A Hemiketal DNP Substrate for In Vivo Metabolic Imaging
Keshari, K. R., Wilson, D. M., Chen, A. P., Bok, R., Larson, P. E. Z., Hu, S., Criekinge, M. V., Macdonald, J. M., Vigneron, D. B., & Kurhanewicz, J. V. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9049355 · Cited by 121
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
“The overflow of free fatty acids (FFAs) coming from lipolysis of adipose tissue is the main contributor to hepatic steatosis [15, 16].”
He, J., Lee, J. H., Febbraio, M., & Xie, W. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011128 · Cited by 116
Norris, G. H., Porter, C. M., Jiang, C., Millar, C. L., & Blesso, C. N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.09.017 · Cited by 125
Zeng, S., Wu, F., Chen, M., Li, Y., You, M., Zhang, Y., Yang, P., Li, W., Ruan, X. Z., Zhao, L., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0157 · Cited by 129
“The homeostasis imbalance of fatty acid metabolism in liver is the key in the development of NAFLD (6).”
Keating, S. E., Sabag, A., Hallsworth, K., Hickman, I. J., Macdonald, G. A., Stine, J. G., George, J., & Johnson, N. A. (2023) · Sports Medicine · doi:10.1007/s40279-023-01918-w · Cited by 119
“Dietary fats, which deliver FFA from the gut via chylomicrons, account for the remaining 15% [13].”
Genetics of nonalcoholic fatty liver disease
Dongiovanni, P., & Valenti, L. V. C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.018 · Cited by 133
“[9] Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ.”
BackgroundLiu, Y., Dang, H., Li, D., Pang, W., Hammock, B. D., & Zhu, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039165 · Cited by 119
“As well, in animal models of high fat (HF)-diet– induced obesity and metabolic disorder, increased fat in the diet is another critical source of excess fat in the liver [5].”
BackgroundThorn, S. R., Baquero, K. C., Newsom, S. A., El Kasmi, K. C., Bergman, B. C., Shulman, G. I., Grove, K. L., & Friedman, J. E. (2014) · Diabetes · doi:10.2337/db14-0276 · Cited by 119
Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 126
“Several studies using stable isotopes have shown that lipogenesis is increased 3 to 5 fold in human NAFLD subjects and can account for up to 25–40% of TG fatty acids [75,76,79,84].”
BackgroundMetabolic Changes of Hepatocytes in NAFLD
Lu, Q., Tian, X., Wu, H., Huang, J., Li, M., Mei, Z., Zhou, L., Xie, H., & Zheng, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.710420 · Cited by 127
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.